文献速递肿瘤 PET/CT骨显像与常规 SPECT

应用[18F]FDG PET进行新辅助化疗早期反应监测可预测肢体骨肉瘤的临床结局

Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma.
PubMed 文献 · EJNMMI Res · 2020-01-03

该回顾性研究纳入73例AJCC II期肢体骨肉瘤患者,在化疗前、1周期后及新辅助化疗结束时行[18F]FDG PET/CT,评估SUVmax及其变化能否预测无事件生存。结果显示PET2的SUVmax、Δ%SUV01和Δ%SUV02是EFS的独立预测因素,1周期化疗后PET评估即可预测临床结局。

要点

  • 73例肢体骨肉瘤患者中36例(49.3%)组织学反应差,17例(23.3%)发生事件(转移15例、局部复发2例)。
  • 多因素分析显示SUV2(RR 8.86,95%CI 2.25-34.93)、Δ%SUV01(RR 5.97,95%CI 1.47-24.25)、Δ%SUV02(RR 6.00,95%CI 1.16-30.91)为EFS独立预测因素。
  • SUV2>5.9或Δ%SUV01>-39.8%或Δ%SUV02>-54.1%者EFS率更差(p<0.05)。

核心结论

  • 1周期术前化疗后行PET评估可预测肢体骨肉瘤的临床结局。
  • [18F]FDG PET在早期评估局部控制时机调整方面显示潜在作用,可作为新辅助化疗早期反应监测的有用手段。

研究设计与样本

  • 回顾性分析73例接受2周期新辅助化疗、手术及辅助化疗的AJCC II期肢体骨肉瘤患者。
  • 所有患者分别在化疗前(PET0)、1周期后(PET1)及新辅助化疗完成后(PET2)行PET/CT。
  • 计算按体重校正的SUVmax及其变化百分比,术后评估组织学反应,采用ROC曲线分析和Cox比例风险模型分析影像及临床病理参数对无事件生存(EFS)的预测价值。

主要发现

  • 36例(49.3%)组织学反应差,17例(23.3%)发生事件(转移15例、局部复发2例)。
  • ROC曲线分析显示PET2的SUVmax(SUV2)、PET0至PET1的SUVmax变化百分比(Δ%SUV01)及PET0至PET2的SUVmax变化百分比(Δ%SUV02)对事件的预测最准确。
  • 多因素分析显示SUV2(相对风险8.86,95%CI 2.25-34.93)、Δ%SUV01(相对风险5.97,95%CI 1.47-24.25)、Δ%SUV02(相对风险6.00,95%CI 1.16-30.91)为EFS的独立预测因素。
  • SUV2>5.9或Δ%SUV01>-39.8%或Δ%SUV02>-54.1%的患者EFS率较其他患者更差(p<0.05)。

关键数值与推荐

  • SUV2阈值为5.9,Δ%SUV01阈值为-39.8%,Δ%SUV02阈值为-54.1%,超过上述阈值者EFS率更差(p<0.05)。
  • 多因素分析EFS的独立预测因素:SUV2相对风险8.86(95%CI 2.25-34.93),Δ%SUV01相对风险5.97(95%CI 1.47-24.25),Δ%SUV02相对风险6.00(95%CI 1.16-30.91)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To propose a personalized therapeutic approach in osteosarcoma treatment, we assessed whether sequential [18F]FDG PET/CT (PET/CT) could predict the outcome of patients with osteosarcoma of the extremities after one cycle and two cycles of neoadjuvant chemotherapy. METHODS: A total of 73 patients with AJCC stage II extremity osteosarcoma treated with 2 cycles of neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy were retrospectively analyzed in this study. All patients underwent PET/CT before (PET0), after 1 cycle (PET1), and after the completion of neoadjuvant chemotherapy (PET2), respectively. Maximum standardized uptake value (SUVmax) (corrected for body weight) and the % changes of SUVmax were calculated, and histological responses were evaluated after surgery. Receiver-operating characteristic (ROC) curve analyses and the Cox proportional hazards models were used to analyze whether imaging and clinicopathologic parameters could predict event-free survival (EFS). RESULTS: A total of 36 patients (49.3%) exhibited a poor histologic response and 17 patients (23.3%) showed events (metastasis in 15 and local recurrence in 2). SUVmax on PET2 (SUV2), the percentage change of SUVmax between PET0 and PET1 (Δ%SUV01), and between PET0 and PET2 (Δ%SUV02) most accurately predicted events using the ROC curve analysis. SUV2 (relative risk, 8.86; 95% CI, 2.25-34.93), Δ%SUV01 (relative risk, 5.97; 95% CI, 1.47-24.25), and Δ%SUV02 (relative risk, 6.00; 95% CI, 1.16-30.91) were independent predicting factors for EFS with multivariate analysis. Patients with SUV2 over 5.9 or Δ%SUV01 over - 39.8% or Δ%SUV02 over - 54.1% showed worse EFS rates than others (p < 0.05). CONCLUSIONS: PET evaluation after 1 cycle of presurgical chemotherapy can predict the clinical outcome of extremity osteosarcoma. [18F]FDG PET, which shows a potential role in the early evaluation of the modification of timing of local control, can be a useful modality for early response monitoring of neoadjuvant chemotherapy.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Lee I, Byun BH, Lim I, et al. Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma. EJNMMI Res. 2020. PMID: 31900594. doi:10.1186/s13550-019-0588-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。